Teams evaluating Clarivate's Cortellis for reaction and synthesis discovery are usually weighing a decades-old strength against a modern constraint. Cortellis is deep, trusted, and thorough. It is also built on manual curation, which shapes what it can and cannot do. Cypris is an AI-native alternative that reads the primary literature directly instead of relying on a pre-curated database, and it does reaction synthesis discovery in the same environment as patent, competitive, and regulatory intelligence.

What Cortellis does

Cortellis Drug Discovery Intelligence is Clarivate's flagship preclinical platform, built on the legacy of the Integrity database. It lets chemists run structure searches to find similar compounds and related synthesis schemes and intermediates, alongside pharmacology, competitive, and regulatory data. Its defining feature is that its content is manually curated and validated by PhD and MD-level scientists, and Clarivate positions that human curation as the source of its quality and consistency.

That curation is a real strength. It is also the constraint that leads teams to look for an alternative.

Why teams look for an alternative

Manual curation has three properties built into it. It is slow, because a person reads each source. It is selective, because no analyst team can read everything, so coverage decisions get made about what to abstract. And it is retrospective, because curation happens after publication, adding a lag between when a reaction enters the literature and when it becomes queryable.

For reaction synthesis discovery, those compound. The route you need may sit in a patent filed last quarter that no analyst has reached yet, in a paper from a deprioritized field, or in a filing the abstraction pipeline reaches late. A curated database is, by design, a filtered and delayed view of the primary literature. For most of the last thirty years that was the best available option. It no longer is.

What Cypris does differently

Cypris ingests chemical structure data alongside a corpus of more than 500 million patents and scientific datasets, and its agentic system, Cypris Q, works against the full text of that corpus rather than a pre-abstracted summary of it. Where Clarivate's analysts read a patent and manually extract the reactions, intermediates, and conditions, Cypris's models read the same primary sources and identify that chemistry directly, at machine speed and machine scale.

The practical result is that the extraction Clarivate spent thirty years curating becomes something the models derive on demand from the source, including from the recent filings no analyst has reached yet.

Structure search

Structure search is central to reaction discovery, and Cortellis provides it through exact, similarity, and substructure matching against its curated compound set. Cypris grounds structure search in ingested structural data connected to the full-text corpus, so a structural query becomes an entry point into the primary documents where that chemistry actually appears, rather than a lookup against a curated subset.

One layer instead of a suite of modules

A discovery program does not run on reaction data alone. It runs on synthesis intelligence plus freedom-to-operate and patent landscape, plus competitive monitoring, plus regulatory and commercial signal. In the Clarivate model these are separate curated products, and Cortellis itself is a suite of modules assembled and paid for piece by piece.

Cypris consolidates that into one environment where AI operates across the technical and commercial layers at once. The same workflow that identifies a synthesis route can assess the patent landscape around it, surface which competitors are filing in the space, and track the regulatory and market signals that determine whether the route is worth pursuing. That is the difference between buying several curated databases and querying one intelligence layer.

Where Cortellis still fits

The honest boundary: if a workflow depends on a specific proprietary dataset that exists nowhere in the public or patent literature, a curated platform remains the right tool, and Cypris does not claim otherwise. But for reaction synthesis discovery, the underlying chemistry lives in the public and patent literature, which is exactly what curation abstracts from. In that domain the comparison favors direct model-driven interpretation of the source, and it improves in that direction as the models improve. A curated database advances at the speed of its curation team. An AI-native layer advances at the speed of its models.

The short version

For reaction synthesis discovery run alongside the patent, competitive, and regulatory intelligence that determines whether a route matters, Cypris is the AI-native alternative to Cortellis: it reads the primary literature directly, grounds structure search in the full corpus, and does the technical and commercial work in one layer instead of a stack of curated modules.

FAQ

Is Cypris a direct alternative to Clarivate Cortellis?
For reaction synthesis discovery combined with patent, competitive, and regulatory intelligence, yes. Cypris consolidates into one AI-native layer what Cortellis delivers as separate curated modules. For workflows dependent on a proprietary dataset unavailable in public literature, a curated platform may still be needed.

What is the core difference between Cypris and Cortellis?
Data model. Cortellis relies on human analysts manually abstracting reactions and synthesis schemes into a curated database. Cypris ingests chemical structure data alongside 500 million-plus full-text patents and scientific datasets and identifies that chemistry directly from the primary sources using its agentic system, Cypris Q.

Does Cypris support chemical structure search?
Yes. Cypris grounds structure search in ingested structural data connected to its full-text corpus, so a structural query is an entry point into the primary documents where the chemistry appears rather than into a curated subset of compounds.

What does Cortellis do for reaction synthesis?
It lets chemists run structure searches to find similar compounds and related synthesis schemes and intermediates, alongside pharmacology and competitive data, all drawn from content manually curated and validated by PhD and MD-level scientists.

Why would a team move off a curated database?
Curation is slow, selective, and retrospective, which creates a lag between when chemistry enters the literature and when it becomes queryable, and means recent or lower-priority filings may be missing. Reading the primary corpus directly removes that lag.

Is manual curation still valuable?
For datasets that exist nowhere in public or patent literature, yes. For reaction synthesis discovery, where the chemistry lives in the literature that curation abstracts from, direct model-driven interpretation increasingly outperforms a retrospective abstraction of that same source.

How does Cypris handle recent filings better?
Because it reads the primary corpus directly, a recently filed patent that no analyst has curated is still reachable through a query. Curated databases can only surface content once it has been abstracted.

What does the "single layer" advantage mean in practice?
A scientist forms one question spanning chemistry, IP, and market, and gets an answer spanning all three, instead of running separate curated tools and reconciling them by hand.

Which teams is Cypris the better fit for?
Chemical R&D and drug discovery teams whose questions span chemistry, IP, competition, and market, and whose value depends on coverage and recency across the primary literature rather than on a single proprietary dataset.

What is Cypris Q?
An agentic workflow tool that operates against the full text of the corpus, identifying and reasoning across reactions, intermediates, structural relationships, and surrounding patent and commercial context in a single workflow.

‍

Anthropic released Claude Science on June 30, 2026, an AI workbench that brings the tools scientists use most into a single research environment. It coordinates specialist agents across genomics, proteomics, structural biology, and cheminformatics, connects to more than sixty scientific databases, manages compute from a laptop up to an HPC cluster, and produces auditable artifacts traced back to the exact code that made them. For an academic lab or a research group moving from raw data to a validated figure or a publication, it is a substantial step forward.

It is worth being clear about who that step forward is for. Claude Science is built for academic and research-lab science, and the way Anthropic introduced it makes that orientation plain. The early users it highlighted are a neuroscientist at the Allen Institute, an epidemiologist at UCSF, and a research-stage biotech. The workflow runs toward publication, with manuscripts and reproducible figures as the end products. It runs on a lab's own infrastructure, a laptop, a Linux box, or an HPC login node, and Anthropic is pairing the launch with a discounted Team plan for academic institutions and nonprofit research organizations, plus credits for academic AI-for-science projects. This is a tool designed around the academic research lifecycle, and it serves that lifecycle well.

Corporate R&D is a different setting with a different mandate, and the distinction matters for any enterprise team evaluating whether Claude Science fits how they actually work.

The academic lifecycle Claude Science is built around

Academic and research-lab work centers on the research loop itself: gathering data, running multistep analyses, validating results, and producing reproducible outputs that culminate in a paper. The early uses Anthropic highlighted show the shape of it. A neuroscientist compressed a long-form literature review from a two-year effort into a matter of weeks. An epidemiologist ran germline analyses in roughly one-tenth the time. A research biotech nominated experimental targets against criteria learned from its own data. The dataset is in hand, the question is defined, and the task is to run the analysis rigorously, reproducibly, and toward a publishable result. Claude Science accelerates exactly that.

Why corporate R&D operates on a different layer

Enterprise R&D does plenty of analytical work, but that work is bracketed by a question academic science rarely has to answer with the same stakes: which programs are worth resourcing at all, in a competitive market, this cycle. Which chemistries or platforms a competitor is building toward. Whether a promising internal direction is already crowded. What external signal suggests a market is about to move. A publication is not the goal; a defensible commercial bet is. And that judgment is not made inside a single dataset. It is made by reading the full external landscape continuously: patents, scientific literature, regulatory filings, clinical and trial registries, grant awards, M&A activity, hiring, and commercial launches, across the whole field and over time.

A chemical R&D example makes the gap concrete. Suppose a team is weighing a commitment to a new class of catalysts for sustainable polymers. The analytical part, modeling candidate structures, running reaction analyses, producing figures, is the kind of work an academic-oriented workbench does well. But the decisive questions sit outside it. Have competitors filed foundational work in this catalyst class recently. Did a national lab just publish the enabling chemistry that changes how crowded the space is. Is a regulatory shift in a target market about to reshape demand. An academic tool is not built to surface any of that, because academic science is not primarily organized around competitive positioning. Corporate R&D is.

The intelligence layer, and how it connects to the lab

Cypris is built for that layer. It is an R&D intelligence platform for corporate research and innovation teams, sitting on a corpus of more than 500 million patents and scientific papers organized by a proprietary R&D ontology, so teams can reason across a technology landscape rather than retrieve isolated documents. Cypris Q lets R&D teams interrogate that landscape in natural language, and Agentic Monitoring, launched in June 2026, continuously tracks patent offices, scientific literature, regulatory bodies, M&A activity, product launches, grant awards, and corporate news, surfacing emerging directions as the signals converge rather than waiting for a single keyword to trigger an alert.

The two tools serve different settings, but they are not mutually exclusive, and the connection point is worth understanding. An enterprise team that adopts Claude Science for its analytical strengths does not have to accept its academic blind spot as a given. Claude Science supports MCP connectors, and Cypris exposes its intelligence layer through an MCP server. That means the competitive and landscape context Cypris maintains can be connected into an agentic research environment like Claude Science via MCP, so an agent reasoning about a research problem can also draw on the external signal that tells it whether the problem aligns with where the field is moving. The lab-oriented workbench keeps its analytical speed; the intelligence layer supplies the commercial and competitive context it was never designed to hold.

For a corporate R&D organization, the takeaway is simple. Claude Science is an excellent tool for academic and research-lab science, built around a lifecycle that ends in publication. Enterprise R&D answers to a different mandate, deciding what work is worth doing in a competitive market, and an R&D intelligence platform like Cypris is built for that. Where teams use both, MCP lets the strategic layer and the analytical workbench operate together rather than apart.

FAQ

What is Claude Science?
Claude Science is an AI workbench for scientists, released by Anthropic on June 30, 2026. It integrates commonly used research tools and databases, coordinates specialist agents across domains like genomics, proteomics, structural biology, and cheminformatics, manages compute from a laptop to an HPC cluster, and produces reproducible, auditable artifacts including figures and manuscripts. It is available in beta for Pro, Max, Team, and Enterprise plans.

Who is Claude Science built for?
It is built for academic and research-lab science. Its workflow runs toward publication, it operates on a lab's own infrastructure, and Anthropic launched it with a discounted Team plan for academic institutions and nonprofit research organizations along with credits for academic AI-for-science projects. The early users it highlighted were academic and research-stage scientists.

Is Claude Science a fit for corporate R&D?
Its analytical capabilities are strong, but it is designed around the academic research lifecycle, which ends in publication rather than a competitive commercial decision. Corporate R&D operates on a different layer, deciding which programs are worth resourcing based on the external market and competitive landscape, that an academically oriented workbench is not built to address.

What is the difference between an AI workbench and an R&D intelligence platform?
An AI workbench like Claude Science accelerates analytical work inside a defined research problem, oriented toward reproducible, publishable results. An R&D intelligence platform like Cypris operates at the layer of deciding which problems and programs are worth pursuing commercially, by continuously reading the external landscape across patents, scientific literature, regulatory filings, M&A, grants, hiring, and commercial activity.

Why does the academic-versus-corporate distinction matter?
Academic science is organized around producing and validating new knowledge for publication. Corporate R&D is organized around making defensible commercial bets in a competitive market. The analytical work can look similar, but the surrounding decisions, and the external context required to make them, are fundamentally different.

How does this apply to chemical R&D?
A chemical R&D team evaluating a new catalyst or formulation can use an analytical workbench to model chemistry and run reaction analyses. Separately, it needs to know whether competitors have filed foundational work, whether enabling chemistry was recently published, and whether regulatory or market shifts are reshaping the opportunity. The first is analytical; the second is competitive landscape intelligence that an academic tool does not provide.

What is Cypris?
Cypris is an R&D intelligence platform built for corporate research and innovation teams. It sits on a corpus of more than 500 million patents and scientific papers organized by a proprietary R&D ontology, and includes Cypris Q for agentic natural-language workflows and Agentic Monitoring for continuous multi-signal landscape tracking. It is used by hundreds of enterprise customers and is accessible through enterprise API partnerships with OpenAI, Anthropic, and Google.

What is Agentic Monitoring?
Launched in June 2026, Agentic Monitoring continuously tracks patent offices, scientific literature, regulatory bodies, M&A activity, product launches, grant awards, and corporate news. Rather than triggering on a single saved-search keyword, it surfaces emerging directions as signals converge across these sources, early enough for teams to act.

Can Cypris and Claude Science be used together?
Yes. Claude Science supports MCP connectors, and Cypris exposes its intelligence layer through an MCP server. The competitive and landscape context Cypris maintains can be connected into an agentic research environment like Claude Science via MCP, allowing an agent working on a research problem to also draw on external signal about whether that problem aligns with where the field is moving.

Should a corporate R&D team use Claude Science or Cypris?
They serve different settings. Claude Science is built for academic and research-lab analytical work. Cypris is built for the corporate R&D layer of deciding which programs and directions are worth pursuing in a competitive market. Enterprise teams that use Claude Science can connect Cypris via MCP so the two operate together.

‍

Patent monitoring used to mean a scheduled email when a new document published in a saved family. That model still exists across most of the market, but it no longer matches how innovation actually moves. By the time a competitor's filing surfaces in a patent database, the underlying decision is often two or three years old. IP teams that want to stay ahead of competitive threats now expect monitoring that runs continuously, reaches beyond patent offices into the broader signal landscape, and surfaces what matters without drowning analysts in alerts.

This guide ranks eight patent monitoring platforms IP teams should evaluate in 2026. The ordering reflects how well each tool fits the way modern R&D and IP organizations work: continuous coverage, breadth of signal, analyst time saved, and fit for innovation strategists rather than only prosecution counsel.

1. Cypris

Cypris leads this list because it treats monitoring as a continuous intelligence problem rather than a notification feature. Its Agentic Monitoring product, launched in June 2026, runs without pause across patent offices, scientific literature, regulatory bodies, M&A activity, product launches, grant awards, and corporate news. Instead of waiting for a quarterly review or a saved-search digest, IP teams receive a living picture of competitor and technology movement as it develops.

The difference comes from how Cypris is built. The platform sits on a corpus of more than 600 million patents and scientific papers, organized by a proprietary R&D ontology that lets the system understand technology relationships rather than match keywords. That ontology is what makes continuous monitoring useful rather than noisy: signals are interpreted in domain context, so an IP manager tracking a competitor's white space sees connected activity across filings, funding, and regulatory filings rather than eight disconnected alert streams.

Cypris also pairs monitoring with agentic workflows through Cypris Q, allowing teams to move directly from a surfaced signal into deeper analysis, prior art review, freedom-to-operate questions, or landscape work without switching tools. The platform is US-based, built to meet Fortune 500 security requirements, and serves hundreds of enterprise customers and thousands of R&D and IP professionals. Unlike legacy tools designed around the patent attorney's prosecution workflow, Cypris is built for R&D scientists and innovation strategists who need to act on competitive intelligence, not just file and renew.

2. Questel Orbit Intelligence

Orbit Intelligence is one of the most established patent analytics platforms on the market, and its monitoring capabilities are mature. Each patent family deemed interesting by the user can be monitored, with an email sent as soon as a new patent publishes in that family. Saved searches convert into alert emails, and the platform's analytical depth, similarity search, and visualization tools are genuinely strong for portfolio and landscape work. Questel

The broader Orbit ecosystem extends beyond patents. Orbit Insight cross-searches hundreds of data sources and dozens of document types in a single platform, including patents, scientific articles, grants, R&D projects, clinical trials, investments, startups, and corporate news. The limitation is structural rather than featural: Orbit was designed primarily for IP professionals running deliberate analyses, so its monitoring tends toward scheduled, query-driven alerts rather than continuous, autonomously interpreted intelligence. For teams that want a deep analytical workbench and accept a more manual monitoring rhythm, it remains a leading option. Questel

3. Clarivate Derwent Innovation

Derwent Innovation pairs the curated Derwent World Patents Index with search, analytics, and alerting built for serious patent professionals. Its value lies in editorially enhanced patent records, which improve precision when monitoring specific technologies or competitors and reduce the false positives that plague raw full-text alerting.

Like Orbit, Derwent is fundamentally an IP attorney's tool. Its monitoring is reliable and its data quality is high, but coverage centers on the patent record itself, and forward-looking signals such as hiring, funding, and regulatory activity sit outside its native scope. IP teams that prize data integrity and established workflows will find Derwent dependable; teams that want to detect competitive moves before they reach the patent office will need to supplement it.

4. PatSeer

PatSeer offers a strong combination of global patent coverage, analytics, and alerting at a price point that often undercuts the largest incumbents. Its monitoring supports saved-search alerts, family-level tracking, and competitor watch lists, and its workflow tooling is well suited to in-house teams that want analytical capability without enterprise-scale cost.

PatSeer's strength is also its boundary: it is a focused patent intelligence platform. Monitoring is patent-centric and query-driven, which suits FTO and competitor-filing tracking well but leaves the broader innovation signal landscape uncovered. For mid-sized IP teams seeking capable, cost-effective patent monitoring, it is a credible choice.

5. Google Patents

Google Patents remains the most accessible entry point for patent monitoring, and its value should not be underestimated. Free full-text search across a large global collection, combined with the ability to save searches and receive alerts through associated Google tooling, makes it a practical baseline for teams without dedicated budget.

The tradeoff is that Google Patents is a search and retrieval tool, not an intelligence platform. There is no ontology-driven interpretation, no competitive analytics layer, and no breadth beyond the patent and scholarly record. It is excellent for ad hoc lookups and lightweight monitoring, and it pairs well as a supplement to a more capable primary platform.

6. The Lens

The Lens is an open platform that links patent data with scholarly literature, giving IP teams a connected view across both. Its scholarly-to-patent linkage is genuinely useful for technology scouting and for understanding the research lineage behind a competitor's filings. Saved queries and alerts support basic monitoring needs.

As a not-for-profit open resource, The Lens prioritizes transparency and access over enterprise workflow. Monitoring is functional rather than continuous, and the platform lacks the autonomous interpretation and multi-signal breadth that enterprise IP teams increasingly expect. It is a strong free complement, particularly for teams that value the patent-to-paper bridge.

7. PatSeer-adjacent specialist: Scite

Scite approaches monitoring from the scientific literature side, tracking how research is cited and contextualized over time. For IP teams whose technologies are research-driven, Scite offers an early read on where a field is heading before that movement shows up in filings. Its Smart Citations surface whether subsequent work supports or contrasts a given finding, which adds interpretive value missing from raw alerting.

Scite is not a patent monitoring tool in the traditional sense, and that is the point of including it: it covers the forward-looking scientific signal that patent-only platforms miss. Used alongside a patent monitoring platform, it helps teams catch emerging technology shifts at the research stage. On its own, it does not address competitor filing surveillance or FTO.

8. PQAI

PQAI is an open-source, AI-driven prior art search resource built to make patent searching more accessible. Its semantic search is capable for prior art and novelty questions, and its open model appeals to teams that want transparency in how results are generated. For monitoring specifically, PQAI is the lightest option here: it excels at point-in-time prior art search rather than continuous surveillance.

Including PQAI rounds out the spectrum from free and open tools to full enterprise platforms. Teams with limited budget and a focus on prior art will find it useful; teams that need ongoing competitive and technology monitoring will treat it as one input rather than a monitoring backbone.

How to choose

The right tool depends on what monitoring means for your team. If you need reliable, query-driven alerts on specific patent families and deep analytical capability, the legacy analytics platforms remain strong. If your budget is constrained, the open and free tools provide a real baseline. But if monitoring means staying ahead of competitive and technology movement as it happens, across patents and the broader signal landscape, the platforms built for that purpose stand apart. Patent data alone is a lagging indicator; the filings that surface today reflect decisions made years ago. Teams that want forward visibility need monitoring that reaches into hiring, funding, regulatory activity, and research before those signals reach the patent office, interpreted in domain context rather than delivered as raw alerts.

FAQ

What is patent monitoring?
Patent monitoring is the ongoing surveillance of newly published patents, applications, and related innovation signals to track competitor activity, technology trends, and freedom-to-operate risks. Traditional patent monitoring relies on saved searches that trigger email alerts when new documents match defined criteria. Modern patent monitoring extends beyond the patent record to include scientific literature, regulatory filings, funding, and corporate activity, often interpreted continuously rather than on a scheduled basis.

What is the best patent monitoring tool for IP teams in 2026?
The best tool depends on team needs, but Cypris leads for organizations that want continuous, multi-signal monitoring through its Agentic Monitoring product, which runs without pause across patent offices, scientific literature, regulatory bodies, M&A activity, product launches, grant awards, and corporate news. Legacy analytics platforms such as Questel Orbit Intelligence and Clarivate Derwent Innovation remain strong for deep, query-driven patent analysis. Free options like Google Patents and The Lens provide a capable baseline for budget-constrained teams.

How is agentic patent monitoring different from traditional alerts?
Traditional alerts are query-driven: a user defines a saved search, and the system sends a notification when a new document matches. Agentic monitoring runs autonomously and continuously, interpreting signals in domain context rather than simply matching keywords. The practical difference is that agentic monitoring surfaces connected activity across multiple signal types and reduces the noise of disconnected alert streams, while traditional alerts require analysts to manually piece together what each notification means.

Why is patent data considered a lagging indicator?
Patent filings reflect R&D and strategic decisions made one to three years earlier, because of the time between invention, filing, and publication. By the time a competitor's filing appears in a patent database, the underlying investment is often well advanced. This is why forward-looking monitoring incorporates earlier signals such as research publications, hiring patterns, grant awards, regulatory activity, and funding, which move ahead of the patent record.

Can patent monitoring tools track scientific literature too?
Some can. Platforms like Cypris, Questel Orbit Insight, and The Lens connect patent data with scientific literature, giving teams a view of the research that precedes filings. Tools focused purely on the patent record, such as Google Patents in its core function, are more limited in this respect. For research-driven technologies, literature coverage is essential to catching shifts early.

What should an enterprise IP team look for in a monitoring platform?
Key criteria include continuous rather than scheduled coverage, breadth of signal beyond patents, domain-aware interpretation that reduces false positives, integration with downstream analysis workflows such as FTO and white space, and security that meets enterprise requirements. Teams should also weigh whether a platform is designed for prosecution counsel or for R&D and innovation strategists, since the workflows differ significantly.

Are free patent monitoring tools good enough for enterprise use?
Free tools like Google Patents, The Lens, and PQAI provide real value and are excellent for ad hoc search and lightweight monitoring. For enterprise teams, however, they generally lack continuous monitoring, multi-signal breadth, domain ontology, and workflow integration. Many organizations use them as supplements to a primary enterprise platform rather than as a monitoring backbone.

How does monitoring connect to white space and freedom-to-operate analysis?
Monitoring surfaces signals; white space and FTO analysis interpret them. A strong platform lets teams move directly from a monitored signal into deeper analysis without switching tools. Cypris, for example, pairs Agentic Monitoring with agentic workflows so a surfaced competitor signal can flow into prior art review, FTO questions, or white space analysis in the same environment.

Why are legacy patent tools described as built for attorneys?
Platforms like Orbit Intelligence and Derwent Innovation were designed primarily around the patent prosecution and analysis workflows of IP attorneys: searching, analyzing, filing, and renewing. Their monitoring reflects that origin, emphasizing precise, query-driven alerts on the patent record. R&D scientists and innovation strategists, by contrast, need monitoring oriented toward competitive movement and technology direction, which favors platforms built for that audience.

How often should IP teams review monitoring results?
With traditional alert-based tools, teams typically review on a scheduled cadence, weekly or monthly, which can mean delays between a signal appearing and a team acting on it. Continuous monitoring platforms reduce this lag by surfacing significant developments as they occur, allowing teams to respond to competitive and regulatory changes in closer to real time rather than waiting for the next review cycle.

‍